These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 9918206)

  • 1. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
    Vasey PA; Kaye SB; Morrison R; Twelves C; Wilson P; Duncan R; Thomson AH; Murray LS; Hilditch TE; Murray T; Burtles S; Fraier D; Frigerio E; Cassidy J
    Clin Cancer Res; 1999 Jan; 5(1):83-94. PubMed ID: 9918206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
    Loadman PM; Bibby MC; Double JA; Al-Shakhaa WM; Duncan R
    Clin Cancer Res; 1999 Nov; 5(11):3682-8. PubMed ID: 10589787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
    Seymour LW; Ferry DR; Anderson D; Hesslewood S; Julyan PJ; Poyner R; Doran J; Young AM; Burtles S; Kerr DJ;
    J Clin Oncol; 2002 Mar; 20(6):1668-76. PubMed ID: 11896118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours.
    Thomson AH; Vasey PA; Murray LS; Cassidy J; Fraier D; Frigerio E; Twelves C
    Br J Cancer; 1999 Sep; 81(1):99-107. PubMed ID: 10487619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1).
    Duncan R; Coatsworth JK; Burtles S
    Hum Exp Toxicol; 1998 Feb; 17(2):93-104. PubMed ID: 9506260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
    Satchi R; Connors TA; Duncan R
    Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
    Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
    Faivre S; Raymond E; Boige V; Gatineau M; Buthaut X; Rixe O; Bernareggi A; Camboni G; Armand JP
    Clin Cancer Res; 2001 Jan; 7(1):43-50. PubMed ID: 11205916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
    Vasey PA; Bissett D; Strolin-Benedetti M; Poggesi I; Breda M; Adams L; Wilson P; Pacciarini MA; Kaye SB; Cassidy J
    Cancer Res; 1995 May; 55(10):2090-6. PubMed ID: 7743508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
    Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C; Häring B; Medinger M; Drevs J; Steinbild S; Kratz F; Mross K
    Clin Cancer Res; 2007 Aug; 13(16):4858-66. PubMed ID: 17699865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer.
    DiPaola RS; Rinehart J; Nemunaitis J; Ebbinghaus S; Rubin E; Capanna T; Ciardella M; Doyle-Lindrud S; Goodwin S; Fontaine M; Adams N; Williams A; Schwartz M; Winchell G; Wickersham K; Deutsch P; Yao SL
    J Clin Oncol; 2002 Apr; 20(7):1874-9. PubMed ID: 11919247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
    Uziely B; Jeffers S; Isacson R; Kutsch K; Wei-Tsao D; Yehoshua Z; Libson E; Muggia FM; Gabizon A
    J Clin Oncol; 1995 Jul; 13(7):1777-85. PubMed ID: 7602367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors.
    Majem M; Salazar R; Garcia M; Clopes A; Muñoz C; Pardo B; Martinez M; Cuadra C; Montes A; Mis R; Savulsky C; Ramon Germa-Lluch J
    J Liposome Res; 2009; 19(4):261-6. PubMed ID: 19863161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.